INR:1955. kerala november yearly chart Heron's new non-opioid painkiller gets 3-month extension in U.S. review GSP certification will be cancelled in ...

This article first appeared on KFF Health News. To view the data, see the original article on the site. In the last few years ...

We recently compiled a list of the Jim Cramer Talked About These 17 Stocks After The Fed’s Rate Cut. In this article, we are ...

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...

The market for non-opioid painkillers is booming in the wake of a devastating overdose crisis and an opioid industry far ...

Plus: Next generation IVF, another successful pig-kidney transplant, worm secretions to treat inflammation, a new skin cancer ...

The Boston drugmaker announced the results of a mid-stage trial of its non-opioid painkiller on Thursday — and its shares ...

From addiction treatment to toy robot ambulances, here's how state and local governments used billions in opioid settlement ...

UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps a Buy rating on the shares.

We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look ...